In acute myeloid leukemia (LAML), both POLR2A and its catalytic subunit RPB1 are aberrantly activated, with RPB1 levels positively correlating with tumor burden and poor outcome (Yu et al., 2019). Here, POLR2A is linked to neoplasm.